Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18-valent meningococcal-pneumococcal combined vaccine
- Development stage
- Preclinical
- Lead developer
- Shandong Kunli Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
18-valent Meningococcal-Pneumococcal Combined Vaccine is a preclinical-stage conjugate combination vaccine being developed by Shandong Kunli Biopharmaceutical. The vaccine is designed to provide broad protection against both meningococcal disease, caused by *Neisseria meningitidis*, and pneumococcal disease, caused by *Streptococcus pneumoniae*. By combining 18 distinct serotypes into a single conjugate formulation, the vaccine aims to simplify immunization schedules while maintaining high immunogenicity through the chemical linkage of bacterial polysaccharides to carrier proteins. This approach is intended to elicit a robust T-cell dependent immune response, which is particularly effective in infants and young children who typically respond poorly to pure polysaccharide vaccines.
- Other names
- 18价流脑肺炎联合疫苗18-valent Meningococcal-Pneumococcal Combined Vaccine
02
Targets
NeuraminidaseCPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on 18-valent meningococcal-pneumococcal combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18-valent meningococcal-pneumococcal combined vaccine.